PULMATRIX INC (PULM)
US74584P3010 - Common Stock
PULM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for PULM as it has an excellent financial health rating, but there are worries on the profitability. PULM shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year PULM has reported negative net income.
In the past year PULM has reported a negative cash flow from operations.
PULM had negative earnings in each of the past 5 years.
PULM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -83.89%, PULM is doing worse than 73.68% of the companies in the same industry.
The Return On Equity of PULM (-88.42%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -83.89% | ||
| ROE | -88.42% | ||
| ROIC | N/A |
ROA(3y)-42.44%
ROA(5y)-47.01%
ROE(3y)-62.76%
ROE(5y)-91.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PULM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PULM does not have a ROIC to compare to the WACC, probably because it is not profitable.
PULM has more shares outstanding than it did 1 year ago.
PULM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PULM has an Altman-Z score of -13.76. This is a bad value and indicates that PULM is not financially healthy and even has some risk of bankruptcy.
PULM has a worse Altman-Z score (-13.76) than 79.47% of its industry peers.
There is no outstanding debt for PULM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.76 |
ROIC/WACCN/A
WACC9.82%
2.3 Liquidity
PULM has a Current Ratio of 19.40. This indicates that PULM is financially healthy and has no problem in meeting its short term obligations.
PULM's Current ratio of 19.40 is amongst the best of the industry. PULM outperforms 93.16% of its industry peers.
A Quick Ratio of 19.40 indicates that PULM has no problem at all paying its short term obligations.
PULM's Quick ratio of 19.40 is amongst the best of the industry. PULM outperforms 93.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.4 | ||
| Quick Ratio | 19.4 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 29.30% over the past year.
Looking at the last year, PULM shows a very strong growth in Revenue. The Revenue has grown by 47.13%.
PULM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 117.48% yearly.
EPS 1Y (TTM)29.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.07%
Revenue 1Y (TTM)47.13%
Revenue growth 3Y-16.71%
Revenue growth 5Y117.48%
Sales Q2Q%-78.89%
3.2 Future
Based on estimates for the next years, PULM will show a very strong growth in Earnings Per Share. The EPS will grow by 22.73% on average per year.
The Revenue is expected to grow by 40.85% on average over the next years. This is a very strong growth
EPS Next Y-18.91%
EPS Next 2Y-14.37%
EPS Next 3Y12.08%
EPS Next 5Y22.73%
Revenue Next Year1%
Revenue Next 2Y1%
Revenue Next 3Y33.81%
Revenue Next 5Y40.85%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
PULM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PULM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PULM's earnings are expected to grow with 12.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.37%
EPS Next 3Y12.08%
5. Dividend
5.1 Amount
No dividends for PULM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PULMATRIX INC
NASDAQ:PULM (12/20/2024, 8:00:01 PM)
After market: 6 0 (0%)6
+0.09 (+1.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners7.16%
Inst Owner Change5.14%
Ins Owners0%
Ins Owner Change0%
Market Cap21.90M
Analysts82.86
Price Target10.2 (70%)
Short Float %1.61%
Short Ratio0.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.19 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.01 | ||
| P/tB | 2.01 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.86
EYN/A
EPS(NY)-5.05
Fwd EYN/A
FCF(TTM)-3.34
FCFYN/A
OCF(TTM)-3.14
OCFYN/A
SpS2.74
BVpS2.99
TBVpS2.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -83.89% | ||
| ROE | -88.42% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.44%
ROA(5y)-47.01%
ROE(3y)-62.76%
ROE(5y)-91.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 502.86% | ||
| Cap/Sales | 7.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 19.4 | ||
| Quick Ratio | 19.4 | ||
| Altman-Z | -13.76 |
F-Score4
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)214.36%
Cap/Depr(5y)160.74%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.07%
EPS Next Y-18.91%
EPS Next 2Y-14.37%
EPS Next 3Y12.08%
EPS Next 5Y22.73%
Revenue 1Y (TTM)47.13%
Revenue growth 3Y-16.71%
Revenue growth 5Y117.48%
Sales Q2Q%-78.89%
Revenue Next Year1%
Revenue Next 2Y1%
Revenue Next 3Y33.81%
Revenue Next 5Y40.85%
EBIT growth 1Y55.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.7%
OCF growth 3YN/A
OCF growth 5YN/A